Pernilla Sandwall, a former executive at Merck & Co Inc, has been appointed head of clinical operations at InDex Pharmaceuticals AB of Sweden. She will lead the company’s clinical development team with the main focus being on a Phase 3 trial of a product for treatment-refractory ulcerative colitis. Ms Sandwall has more than 20 years of experience in clinical research. She has a master of science in pharmacy from Uppsala University.
InDex Pharmaceuticals also announced the appointment of Thomas Knittel as chief medical officer. Dr Knittel was formerly a business unit director at Novo Nordisk. He has a medical degree from the University of Mainz with specialist training in internal medicine and gastroenterology.
Copyright 2012 Evernow Publishing Ltd